At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 209 enrolled
Drug / intervention
GSK Biologicals' GSK2340274A (two different formulations) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observer-blind Safety and Immunogenicity Study of GSK Biologicals' A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340272A in Children 3 to Less Than 10 Years Old
In Brief
A Phase 2 clinical trial evaluating GSK Biologicals' GSK2340274A (two different formulations) and GSK Biologicals' - GSK2340272A for Influenza. Completed, enrolled 209 participants across 2 sites in 2 countries.
Detailed Summary
This study is designed to characterize the safety and immunogenicity of pandemic influenza (H1N1) candidate vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years old.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesPhilippines, Thailand
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedJul 2010
Primary CompletionAug 2010
Study CompletionJan 2011
TodayJul 2026
First PostedJul 13, 2010
Enrollment StartJul 1, 2010
Primary CompletionAug 23, 2010
Study CompletionJan 31, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.0 years ago
Interventions
GSK Biologicals' GSK2340274A (two different formulations)biological
Intramuscular injection
GSK Biologicals' - GSK2340272Abiological
Intramuscular injection